Table 1 Relationships between SEMA4D mRNA expression and baseline characteristics of patients with AML from cBioportal
From: SEMA4D/PlexinB1 promotes AML progression via activation of PI3K/Akt signaling
Clinical characteristics | Total | SEMA4D low (n = 95) | SEMA4D high (n = 78) | P-value |
|---|---|---|---|---|
Age | ||||
 < 60 | 91 | 53 [58.2%] | 38 [41.8%] | 0.354 |
 > 60 | 82 | 42 [51.2%] | 40 [48.8%] |  |
Gender | ||||
 Male | 92 | 53 [57.6%] | 39 [42.4%] | 0.448 |
 Female | 81 | 42 [51.9%] | 39 [48.1%] |  |
Risk vs. favorable | ||||
 Favorable | 32 | 27 [81.3%] | 5 [18.8%] |  |
 Intermediate | 101 | 44 [40.6%] | 57 [59.4%] | 0.000 |
 Adverse | 37 | 22 [48.6%] | 15 [51.4%] | 0.002 |
 Missing | 3 | 2 [66.7%] | 1 [33.3%] |  |
Lab examinations | ||||
 WBC |  | 22.9 (3.4–57.1) | 14 (3.05–51.95) | 0.519 |
 BM |  | 72 (54–86) | 75 (50.75–85.25) | 0.905 |
 PB |  | 45 (7.25–72) | 27 (7.75–58.75) | 0.123 |